TAF15 and cancer: In the TCGA RNA-Seq lung adenocarcinoma patient dataset, although a difference in survival was not observed until 2000 days, none of the patients having high TAF15 levels in their cancer survived, as compared to 30% overall survival in patients with low levels of TAF15 (Figure 1).